<DOC>
	<DOCNO>NCT00004935</DOCNO>
	<brief_summary>RATIONALE : To compare efficacy , toxicity quality life sequential administration Her alone follow , PD , combination Chemotherapy ( Arm A ) vs. upfront combination Her Chemotherapy ( Arm B ) patient advanced/metastatic breast cancer . PURPOSE : Trial SAKK 22/99 address clinically relevant currently unresolved question regard optimal use Herceptin treatment patient advanced/metastatic breast cancer .</brief_summary>
	<brief_title>Herceptin Followed Chemotherapy Treating Women With Metastatic Breast Cancer That Overexpresses HER2</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm HER2overexpressing metastatic breast carcinoma Clinically radiologically measurable evaluable disease Bidimensionally unidimensionally measurable lesion No ascitic , pleural , pericardial effusion , osteoblastic bone metastasis , carcinomatous lymphangitis lung indicator lesion No known clinical brain meningeal involvement Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 70 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 OR SAKK 01 Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 10 g/dL Platelet count least 100,000/mm^3 Absolute neutrophil count least 2,000/mm^3 Hepatic : Bilirubin normal SGOT and/or SGPT great 2 time upper limit normal ( ULN ) ( 3 time ULN proven liver metastasis ) OR No SGOT and/or SGPT great 1.5 time ULN alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.25 time ULN Cardiovascular : LVEF normal No history atrial ventricular arrhythmia , congestive heart failure , angina pectoris , even medically control No history second thirddegree heart block No uncontrolled hypertension Other : Not pregnant nursing Fertile patient must use effective contraception No preexisting motor sensory neuropathy grade 2 great No psychiatric disorder would preclude informed consent No prior malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix No definite contraindication use corticosteroids No concurrent serious illness medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior adjuvant neoadjuvant chemotherapy allow No 2 prior chemotherapy regimens metastatic disease No prior cumulative dose doxorubicin great 240 mg/m^2 No prior cumulative dose epirubicin great 360 mg/m^2 No prior taxanes Endocrine therapy : Prior hormonal therapy adjuvant treatment metastatic disease allow No concurrent corticosteroids unless start 6 month prior study low dos ( i.e. , great 20 mg methylprednisolone equivalent ) Radiotherapy : Not specify Surgery : Not specify Other : No concurrent anticancer drug No concurrent experimental drug No concurrent bisphosphonates unless initiate 3 month prior study Chronic use allow provided bone metastasis sole indicator lesion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>